A Crossover Trial of Chitosan Oligosaccharide on Post Prandial Glucose Control in Subjects With N… (NCT03650023) | Clinical Trial Compass
CompletedNot Applicable
A Crossover Trial of Chitosan Oligosaccharide on Post Prandial Glucose Control in Subjects With Normal, IFG and IGT
South Korea37 participantsStarted 2018-05-09
Plain-language summary
It is well known that Chitosan oligosaccharide is low molecular weight and water soluble and chitosan oligosaccharide has been shown to reduce blood cholesterol and blood pressure, increase immunity, and enhance antitumor properties. the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with normal blood glucose, impaired fasting glucose and impaired glucose tolerance.
Who can participate
Age range20 Years – 74 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Normal Blood Glucose (fasting blood sugar below 100mg/dl, two hours after meals below 140mg/dl)
* Impaired Fasting Glucose (fasting blood sugar 100-125mg/dl)
* Impaired Glucose Tolerance (two hours after meals 140-199mg/dl)
Exclusion Criteria:
* history/presence of diabetes mellitus (including oral hypoglycaemic agent and insulin)
* history of serious hypoglycemia
* history of serious cardiovascular, cerebrovascular disease, pulmonary, gastrointestinal, hepatic, renal and/or haematological disease
* uncontrolled blood pressure (blood pressure level more than 140/90mmHg)
* history/presence of alcoholism, drug addiction, etc.
* taking a regulation of blood glucose medications within 1 month before study
* participation other intervention studies within 1 months before study
* history of diagnosed with cancer, cancer surgery and hospitalization
* women who are pregnant or desire to become pregnant during the study period
* having any other medical condition which, in the opinion of the investigator, could interfere with participation in the study